Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406852 | 1.00 | HIF1A (1.00) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610116 | 0.96 | HIF1A (1.00) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL4778141 | 0.90 | HIF1A (0.82) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610042 | 0.90 | HIF1A (0.86) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL4508960 | 0.89 | HIF1A (0.81) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610265 | 0.89 | HIF1A (1.00) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL15413771 | 0.88 | HIF1A (0.80) | HIF1AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4526805 | 0.86 | HIF1A (0.76) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610375 | 0.86 | HIF1A (0.82) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL14303700 | 0.86 | HIF1A (0.83) | HIF1AALDH1A1SMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | LIFECEUTIX CO., LTD. (KR) | 2025-04-03 | — | — | US | disclosed |
| US-20240415869-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS | NOVOCURE GMBH (CH) | 2024-12-19 | — | — | US | disclosed |
| WO-2024257051-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS | NOVOCURE GMBH (CH) | 2024-12-19 | — | — | WO | disclosed |
| CN-118994161-A | (S) -2- (4- (4-methyl-1-piperazinyl) anilino) -8-anilino-9- (3-piperidinyl) -9H-purine and application thereof | 西安交通大学医学院第一附属医院 | 2024-11-22 | — | — | CN | disclosed |
| EP-4431102-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | Lifeceutix Co., Ltd. (KR) | 2024-09-18 | — | — | EP | disclosed |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | NQO1, HNMT, PNMT | HIF1A 1918/4885ALDH1A1 288/4885SMN1; SMN2 2602/4885 |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | GLA, LIMS1, TP53 | HIF1A 1737/4885ALDH1A1 668/4885SMN1; SMN2 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.